N(alpha)-Boc-N(omega)-tosyl-L-arginine (CAS 13836-37-8), almost universally known as Boc-Arg(Tos)-OH, is a fully protected derivative of L-arginine carrying an acid-labile Boc group on the α-amino function, a tosyl (p-toluenesulfonyl) group on the side-chain guanidine, and a free carboxylic acid at the C-terminus. Its molecular formula is C₁₈H₂₈N₄O₆S, with a molecular weight of 428.50 g/mol. The commercial significance of this molecule is inseparable from the chemistry of Boc/Bzl solid-phase peptide synthesis. Arginine’s guanidine side chain is the most nucleophilic and hydrogen-bonding-rich function among the proteinogenic amino acids, and unprotected it interferes with coupling, acylation and chain assembly. The Tos group solves that problem not by being labile under the conditions of chain elongation, but by being exceptionally stable under them. Tos-protected arginine survives repeated trifluoroacetic acid (TFA) treatments during Boc deprotection cycles, remains intact through coupling with DCC, HATU, HBTU or PyBOP, and is removed only at the final anhydrous hydrogen fluoride (HF) cleavage step. That stability profile is the reason Boc-Arg(Tos)-OH is the default arginine building block for Boc SPPS, and the reason it avoids the incomplete-deprotection and side-reaction problems that plague Mtr-based arginine analogs. The demand context is the peptide therapeutics market: the global peptide synthesis market is projected to grow from USD 746.7 million in 2025 to USD 1,640.5 million by 2034 at a 9.39% CAGR, and Boc SPPS accounts for an estimated 70–75% of Boc-Arg(Tos)-OH consumption. For buyers, the qualifying question is not whether the molecule works—the Tos strategy is well established—but whether a given lot delivers the enantiomeric purity, moisture control and coupling reproducibility that a long peptide sequence demands.
Core Application Fields and Demand Architecture
Demand for Boc-Arg(Tos)-OH concentrates in four functional arenas where the orthogonal protection of arginine’s guanidine is a precondition for successful chain assembly: Boc solid-phase peptide synthesis, peptide-based drug substance manufacturing, conjugate and bioconjugation chemistry, and diagnostic and research applications.
In Boc solid-phase peptide synthesis, Boc-Arg(Tos)-OH is the standard building block for introducing arginine residues. The Tos group’s defining advantage is its inertness during chain elongation: whereas Mtr-protected arginine can undergo partial cleavage under repeated TFA exposure, leading to side reactions, truncated sequences and reduced yield, the Tos group remains intact across all coupling and deprotection cycles and is quantitatively removed only during final HF cleavage. This makes Boc-Arg(Tos)-OH compatible with both manual SPPS workflows and fully automated peptide synthesizers, as well as with large-scale solution-phase synthesis for generic peptide APIs. Boc SPPS accounts for approximately 70–75% of total Boc-Arg(Tos)-OH consumption, which means the product’s demand is structurally tied to the Boc/Bzl segment of the peptide manufacturing industry rather than to Fmoc chemistry, where Pbf or Pmc protection dominates.
In peptide-based drug substance manufacturing, Boc-Arg(Tos)-OH is a key building block for active pharmaceutical ingredients including GLP-1 agonists such as semaglutide and liraglutide, peptide antibiotics such as polymyxin B and colistin, peptide hormones and analogs, renin inhibitors and HIV protease inhibitors. In these molecules, arginine residues are not incidental: they contribute positive charge, hydrogen-bonding capacity and membrane-interaction properties that determine receptor binding, membrane penetration and tertiary folding. Correctly incorporating multiple arginine residues at defined positions is therefore a critical quality attribute, and the building block’s enantiomeric purity and coupling efficiency directly influence whether the final peptide meets its specification. The GLP-1 segment is particularly consequential: semaglutide and liraglutide contain arginine residues at defined positions, and the scale-up of generic and biosimilar GLP-1 manufacturing is pulling through demand for high-purity arginine building blocks.
In antibody-drug conjugate (ADC) and peptide-drug conjugate (PDC) development, Boc-Arg(Tos)-OH serves as a building block for linker peptides and bioconjugation handles. Arginine-rich linker sequences are used to modulate solubility, cell penetration and enzymatic release, and the protected arginine monomer allows those sequences to be assembled without side-chain interference. This application segment is smaller in volume than peptide API manufacturing but is growing as conjugate modalities expand.
Diagnostic reagents and research applications complete the demand base. Boc-Arg(Tos)-OH is used in the synthesis of arginine-containing peptides for ELISA development, lateral flow immunoassays and point-of-care tests, as well as in studies of protein–protein interactions, enzyme inhibition and cellular signaling where arginine residues play a functional role. These applications are fragmented and small in mass, but they value the same attributes as the pharmaceutical segments: reproducible coupling, defined stereochemistry and lot-to-lot consistency.
Regulatory Profile: A Non-Hazardous Building Block Defined by Inventory Status, Enantiomeric Purity and Moisture Control
Boc-Arg(Tos)-OH is not a CMR substance and is not classified as a hazardous material for transport. Its regulatory identity is defined instead by inventory listings, a mild irritancy classification in some SDS documentation, and the analytical specifications that determine whether the material is fit for peptide synthesis.
The transport and hazard classification is favourable. The compound is not classified as a hazardous material for transport (non-hazmat) and is not DEA-regulated. Merck’s SDS for the Novabiochem grade classifies the substance as “not a dangerous substance or mixture” under GHS, with no hazard pictograms, signal word or hazard statements required. Some supplier SDS documentation, however, reports H319 (causes serious eye irritation) and EUH066 (repeated exposure may cause skin dryness or cracking), reflecting a Category 2 eye irritation classification in those assessments. The practical implication is that handling requires standard laboratory precautions—eye protection and gloves—but not the containment infrastructure associated with CMR or water-reactive materials. This distinguishes Boc-Arg(Tos)-OH sharply from reagents such as lithium borohydride or trifluoroacetic acid, and it simplifies both laboratory use and international shipment.
Inventory status varies by jurisdiction and is a qualification checkpoint rather than a barrier. In the United States, the compound is TSCA listed for research use; in China, it is listed in the IECSC; and in the European Union it is subject to REACH obligations, with an EINECS number of 237-549-2. For Russian and EAEU buyers, the practical documentation requirements are a Certificate of Analysis, a Russian-language SDS where required, and confirmation that the material meets the peptide-synthesis specification rather than a generic research-grade claim.
The analytical specifications are where the regulatory and quality dimensions converge. Peptide synthesis demands enantiomeric purity, because a D-arginine epimer introduced during chain assembly produces a diastereomeric peptide that is difficult to separate and may be pharmacologically inactive or immunogenic. Commercial specifications for Boc-Arg(Tos)-OH typically require HPLC assay ≥99.0%, TLC purity ≥98%, D-enantiomer ≤0.5%, moisture <0.5% by Karl Fischer titration, and a specific optical rotation of [α]²⁰D = −3.5 ± 1° (c = 4 in DMF), which confirms the L-configuration. Moisture control is not a cosmetic specification: water in the building block can hydrolyse activated carboxylates and reduce coupling efficiency, and a lot that has absorbed moisture during storage or transport will underperform even if the HPLC purity figure is unchanged.
Global Supply Structure and Manufacturer Differentiation
Global Boc-Arg(Tos)-OH supply is moderately concentrated at the quality end and fragmented at the catalogue end. The suppliers identified in product and market documentation include Sigma-Aldrich (Merck KGaA) through its Novabiochem line, BOC Sciences, Chem-Impex, Alfa Chemistry, EvitaChem, Combi-Blocks, Finetech and a range of specialised manufacturers, with Asian CRO/CDMO outsourcing having significantly expanded procurement from cost-effective but high-quality producers. The Novabiochem grade is positioned as a reference material with assay ≥98% by TLC and ≥99.0% by HPLC, crystallised with approximately 10% w/w ethyl acetate, and supplied with a full analysis certificate covering optical rotation, solubility and appearance.
Differentiation operates on three axes that matter more to a peptide chemist than the headline purity figure. The first is enantiomeric purity and optical rotation control. A Boc-Arg(Tos)-OH lot with D-enantiomer above 0.5% introduces a diastereomeric impurity that propagates through every subsequent coupling, and the resulting peptide may require chromatographic separation or may fail specification altogether. Suppliers that report D-enantiomer and specific rotation on a lot-specific basis, rather than a catalogue nominal, give the process chemist a defensible basis for use in a validated synthesis. The second axis is moisture and residual solvent control. Boc-Arg(Tos)-OH is hygroscopic to a degree, and moisture above specification reduces coupling efficiency. The Novabiochem product is crystallised with ethyl acetate and carries approximately 2% water as a typical impurity, which means the drying and packaging protocol is part of the product’s performance. A supplier that controls moisture below 0.5% by Karl Fischer and documents residual solvent against ICH Q3C expectations reduces the risk of a failed coupling campaign. The third axis is supply scale and documentation depth. The molecule moves from gram-scale medicinal chemistry to kilogram-scale peptide manufacturing, and a supplier that can follow that transition without changing the analytical method or the impurity profile is more valuable than a catalogue vendor that cannot support scale-up. Finetech’s listing of supply from grams to bulk, with COA, SDS, HPLC and NMR documentation and custom synthesis for non-catalogue analogs, illustrates the service dimension that process-scale buyers expect.
For Russian and EAEU buyers, the supply structure creates a familiar import dependency. Domestic production of peptide-grade Boc-Arg(Tos)-OH is limited, and supply is sourced from European, Indian and Chinese producers through catalogue and custom-synthesis channels. The practical qualification burden falls on incoming QC: verifying HPLC assay, D-enantiomer, moisture and optical rotation against the certificate of analysis, and confirming that the material has been stored and shipped under conditions that preserve those specifications.
Regional Demand Dynamics
Boc-Arg(Tos)-OH demand follows the geography of peptide synthesis and peptide API manufacturing rather than the geography of amino acid production.
Europe and North America are the mature, specification-intensive markets. They concentrate the peptide discovery and process chemistry groups of large pharmaceutical companies, the CRO/CDMO sector that serves them, and the generic peptide API manufacturers that use Boc/Bzl SPPS for cost-sensitive, high-volume peptides. Demand is specification-driven and relatively insensitive to price at the gram scale, because the building block cost is a small fraction of the peptide batch value and a failed coupling is far more expensive than the reagent. The presence of established reference-grade suppliers provides regional supply security, but the qualification bar remains high: D-enantiomer, moisture and optical rotation must be documented lot by lot.
Asia-Pacific is the fastest-growing region and the manufacturing and stock-holding hub for Boc-Arg(Tos)-OH. The expansion of peptide API manufacturing in China, India, South Korea and Japan, combined with the growth of the CRO/CDMO sector serving global pharmaceutical companies, has increased procurement of high-purity Boc-Arg(Tos)-OH from Asian producers. The region’s demand is bifurcated between industrial-grade material for cost-sensitive generic peptide production and high-purity material for GLP-1 agonists and complex peptides, and the gap between those tiers is widening as peptide therapeutics specifications tighten.
Russia and the EAEU form a smaller, import-dependent contour. Demand comes from peptide research, generic peptide API manufacturing and diagnostic reagent production, and supply is sourced from international catalogue vendors and custom-synthesis houses. There is no large-scale domestic production of peptide-grade Boc-Arg(Tos)-OH, and the practical constraints are availability at the required enantiomeric purity and documentation that supports incoming qualification. Buyers in the region place a premium on suppliers that can provide lot-specific HPLC and chiral data, a Russian-language SDS and reliable delivery of the gram-to-kilogram quantities that peptide development programs require.
Future Outlook and Strategic Imperatives
The Boc-Arg(Tos)-OH market will grow at a rate tied to peptide therapeutics manufacturing, not to the broader fine chemical cycle. The peptide synthesis market is forecast to expand at a 9.39% CAGR through 2034, and the Boc SPPS segment—which accounts for 70–75% of Boc-Arg(Tos)-OH consumption—will grow with it as generic GLP-1 agonists, peptide antibiotics and complex peptide APIs scale up. Fmoc chemistry will continue to dominate many new peptide programs, but Boc/Bzl SPPS retains a structural role in cost-sensitive and large-volume peptide manufacturing, and the Tos protection strategy remains the standard for arginine in that segment.
Three structural forces will shape competition. First, enantiomeric purity and moisture control will remain the differentiators that separate peptide-grade suppliers from catalogue vendors. As peptide APIs become more complex and specifications tighten, a D-enantiomer specification of ≤0.5% and moisture below 0.5% will be baseline expectations rather than premium features. Second, the shift of peptide API manufacturing toward Asian CRO/CDMOs will continue to expand procurement from cost-competitive producers, but it will also raise the documentation bar: buyers will require lot-specific chiral HPLC, residual solvent and elemental impurity data, not just a nominal purity figure. Third, scale-up capability will matter more as generic GLP-1 and peptide antibiotic programs move from development to commercial production, and suppliers that can hold a locked specification from grams to kilograms will be preferred over those that cannot.
For Russian and EAEU buyers, the strategic implication is that Boc-Arg(Tos)-OH procurement should be treated as an analytical-specification partnership rather than a price comparison. A lot with D-enantiomer above the specification, or moisture that has compromised coupling efficiency, does not simply cost the price of the bottle; it can invalidate a peptide batch, delay a process qualification or force a chromatographic purification that erodes yield. The lowest-risk supplier is the one that can provide lot-specific HPLC and chiral data, a defined moisture specification, optical rotation confirmation and Russian-language documentation that supports incoming qualification.
Shanghai XinChem Co., Ltd. (XinChem)
As a world-leading supplier of organic chemicals, Shanghai XinChem Co., Ltd. (XinChem) offers N(alpha)-Boc-N(omega)-tosyl-L-arginine (Boc-Arg(Tos)-OH, CAS 13836-37-8) in peptide-synthesis and high-purity grades, serving peptide API manufacturers, CRO/CDMO organizations, generic peptide producers and diagnostic reagent developers. Our Boc-Arg(Tos)-OH is supplied with lot-specific chiral HPLC and moisture data, controlled D-enantiomer content and optical rotation confirmed against the L-configuration, supported by the analytical documentation and Russian-language SDS that peptide-synthesis qualification requires.
Technical and Quality Advantages
Enantiomeric Purity and Optical Rotation Control: Boc-Arg(Tos)-OH is supplied with D-enantiomer controlled at ≤0.5% and specific optical rotation reported on a lot-specific basis ([α]²⁰D = −3.5 ± 1°, c = 4 in DMF). Because a D-arginine epimer propagates through every subsequent coupling and produces a diastereomeric peptide, lot-level chiral data is the specification that matters most in complex peptide synthesis, not the headline HPLC purity alone.
Moisture and Residual Solvent Documentation: Moisture is controlled below 0.5% by Karl Fischer titration, and residual solvent is documented against the applicable specification. Water in the building block can hydrolyse activated carboxylates and reduce coupling efficiency, so a dried and well-documented lot protects the coupling campaign even when the HPLC purity figure is unchanged.
HPLC and TLC Specification: Material is available at HPLC assay ≥99.0% and TLC purity ≥98%, consistent with the specifications used for peptide-synthesis-grade Boc-Arg(Tos)-OH. The certificate of analysis reports assay, appearance, optical rotation, solubility and moisture for the specific lot, allowing the buyer to qualify the material against the peptide program’s requirements without re-characterization.
Scale-Up and Documentation Continuity: Boc-Arg(Tos)-OH is available from gram-scale research quantities through to kilogram and multi-kilogram custom-synthesis volumes, with the analytical method and impurity profile held constant across scales. This continuity reduces the re-qualification burden when a peptide program advances from development to commercial production.
Packaging and Logistics Flexibility
Boc-Arg(Tos)-OH is available in sealed 5 g, 25 g and 100 g containers for research and pilot qualification, and in 1 kg and larger package sizes for process-scale peptide manufacturing. Storage at 2–8°C in a dry, light-protected container preserves the specification for at least 24 months. For Russia and EAEU destinations, XinChem arranges logistics with appropriate customs and transport documentation, including Russian-language SDS and Certificate-of-Analysis support, to reduce clearance friction and qualification delay.
Application Support and Supply Reliability
XinChem’s technical team assists with grade selection for Boc/Bzl SPPS, GLP-1 agonist and peptide antibiotic manufacturing, ADC linker synthesis and diagnostic peptide production, and with the enantiomeric purity, moisture and optical rotation documentation that peptide-synthesis qualification demands. Supply schedules accommodate both catalogue-scale qualification orders and process-scale volumes, with stock held for the package sizes most commonly requested in peptide development and manufacturing programs.
Why Choose XinChem
Expertise: Deep experience in Boc-protected amino acids and peptide building blocks, with application knowledge spanning Boc SPPS, peptide API manufacturing and bioconjugation chemistry.
Consistency: Lot-specific control of enantiomeric purity, moisture and optical rotation—the parameters that determine whether Boc-Arg(Tos)-OH incorporates cleanly into a growing peptide chain or introduces a diastereomeric impurity that requires purification.
Compliance Readiness: Documentation structured around peptide-synthesis specifications, inventory listings including TSCA and IECSC, and EAEU documentation expectations, with Russian-language SDS support.
Responsiveness: Direct technical and commercial access, with order structures from gram-scale qualification to multi-kilogram process supply.
Contact us now to discuss your Boc-Arg(Tos)-OH requirements and request a specification sheet or qualification sample.
Website: www.xinchem.com
Email: sales1@xinchem.com
WhatsApp: +86 18049800532
Post time: Oct-28-2026